Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)

Esophageal Squamous Cell Carcinoma Clinical Trial

— TINES  

Official title:

A Randomized, Open-label, Uncontrolled Study of Tislelizumab in Combination With Chemotherapy or Radiation Therapy for Neoadjuvant Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (TINES)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05603065
• Other study ID #: No. XJTU1AF2022LSK-374
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: October 10, 2022
• Est. completion date: October 2024

Study information

• Verified date: October 2022
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Esophageal squamous cell carcinoma (ESCC), one of the most common subtypes of esophageal cancer, has a poor prognosis and low 5-year overall survival. At present, the treatment of ESCC includes chemotherapy, immunity, radiotherapy, surgery and other methods, and in recent years, the treatment regimen of immune combined chemotherapy has begun to show results in the treatment of esophageal cancer. Tislelizumab has demonstrated good efficacy in advanced esophageal cancer and in the second- and third-line treatment. At present, neoadjuvant immunization is carried out less, and neoadjuvant immunization plus chemoradiotherapy has been achieved With a pCR rate of 55.6 and AEs of grade III and above 65%, and studies have shown that radiotherapy has immunosensitizing and coordinating effects, whether immunotherapy combined with radiotherapy has a better efficacy is worth further investigation. This review intends to conduct a randomized, open-label, uncontrolled study of tislelizumab in combination with chemotherapy or radiation therapy for neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma with a view to providing a new option for resectable locally advanced ESCC.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 32
• Est. completion date: October 2024
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• (1) The subjects voluntarily joined the study and signed the informed consent form, with good compliance and follow-up;

• (2) 18 years old= age= 79 years old, male or female;

• (3) ECOG score 0~1 points;

• (4) Patients with pathological (histological or cytology) confirmed esophageal squaf cell carcinoma; According to the eighth edition of the clinical tumor TNM stage, subjects were resectable cT2-4aNanyM0;

• (5) Have measurable lesions (according to RECIST 1.1 criteria, tumor lesion CT scan length diameter= 10mm lymph node lesion CT scan short diameter =15mm);

• (6) Those who were first diagnosed with esophageal squamous cell carcinoma before enrollment and did not undergo radiotherapy, chemotherapy, immunity, surgery and targeted therapy;

• (7) Able to eat a liquid diet or above, no signs before esophageal perforation or esophageal ulcers, and able to tolerate surgery;

• (8) The main organs function normally, that is, meet the following standards:

1. Routine blood examination must be consistent (no blood transfusion, no hematopoietic factor and no correction with drugs within 14 days): ANC=1.5×109/L; PLT=100×109;HB=90g/L;

2. Biochemical tests must meet the following standards: TBIL=1.5×ULN; ALT?AST=2.5×ULN; serum creatinine sCr=1.5×ULN, endogenous creatinine clearance=50mL/min (Cockcroft-Gault formula); ALB=30g/L;

3. The coagulation function must meet: INR=1.5×ULN and APTT=1.5×ULN;

4. Normal or mild to moderate lung function and can tolerate esophageal cancer surgery. Preoperative lung function examination should meet: VC% > 60%; FEV1 > 1.2 L,FEV1% > 40%; DLco>40%?

Exclusion Criteria:

• (1) Have any active autoimmune disease or history of autoimmune disease (as follows, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy)); Patients with vitiligo or childhood asthma that have been in complete remission and do not require any intervention in adulthood are excluded, but patients requiring medical intervention with bronchodilators are not included;

• (2) Patients with congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B, hepatitis C or co-infection with hepatitis B and C;

• (3) immunosuppressive drugs have been used within 14 days prior to first use of study drug, excluding nasal and inhaled corticosteroids or physiologic doses of systemic steroids (i.e., not more than 10mg/day prednisone or its equivalent);

• (4) The patient lost = 10% body weight within 6 months before enrollment, or the BMI < 18.5kg/m2, or PG-SGA reached grade C;

• (5) Live attenuated vaccine within 4 weeks prior to the first dose or planned for the duration of the study;

• (6) other malignant tumors in the past 3 years;

• (7) uncontrolled hypertension (systolic blood pressure = 140 mmHg or diastolic blood pressure = 90 mmHg, despite optimal medical therapy); Patients with a new diagnosis of angina within 3 months prior to screening or myocardial infarction events within 6 months prior to screening; Arrhythmias (including QTcF: =450ms for men and 470ms = women) require long-term use of antiarrhythmic drugs and grade II cardiac insufficiency = New York Heart Association;

• (8) Those with a history of severe lung or heart disease;

• (9) Complicated by severe infection (eg, requiring intravenous antibiotics, antifungal or antiviral drugs) within 4 weeks before the first dose, or unexplained fever >38.5°C during screening/before the first dose;

• (10) Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;

• (11) Pregnant or lactating women; Patients of childbearing potential who are unwilling or unable to use effective contraception;

• (12) Known allergic reactions, hypersensitivity reactions or intolerances to investigational drugs and their excipients;

• (13) Subjects who are participating in other clinical studies or whose first dose is less than 4 weeks from the end of the previous clinical study (last dose), or who have 5 half-lives of the study drug;

• (14) Subject has a known history of psychotropic substance abuse, alcohol or drug abuse;

• (15) Any condition that the investigator believes is likely to harm the subject or cause the subject to be unable to meet or perform the study requirements;

• (16) After neoadjuvant therapy, the patient cannot tolerate surgery or is not suitable for surgery due to the progression of the disease.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

Intervention

Drug:
• Tislelizumab + cisplatin + paclitaxel
Tislelizumab 200mgD1 + cisplatin 75mg/m^2D1 + paclitaxel 150mg/m^2D1 Q3W 3 cycles
• Tislelizumab + radiotherapy
Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response rate (pCR)	postoperative pathological examination shows no carcinological tissue residue	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks
Secondary	Primary pathologic response rate (MPR)	postoperative pathological examination shows a residual < of 10% of cancerous tissue	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks
Secondary	Objective response rate (ORR) of primary lesions (RECIST v1.1)	the proportion of patients whose tumors shrink to a certain amount and remain for a certain period of time under imaging measurements, including complete response (CR, Complete Response) and partial response (PR, partial response) cases CR is defined as the complete disappearance of all target lesions except nodular disease. All target nodules must be reduced to normal size (minor axis< 10 mm). All target lesions must be evaluated.; PR is defined as the sum of the diameters of all measurable target lesions less than 30% = baseline. The target nodule is summed and the short diameter is used, while all other target lesions are combined and the longest diameter is used. All target lesions must be evaluated.	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks
Secondary	Disease-free survival (DFS)	the time between postoperative surgery and recurrence of disease or death (for any cause)	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks
Secondary	Over all survival (OS)	the time from postoperative surgery to death (for any reason)	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks
Secondary	Safety in the neoadjuvant phase and postoperative phase	according to the Common Acute and Subacute Toxicity Grading Standard (CTCAE 5.0), the adverse reactions after each immune combined radiotherapy or immune combined chemotherapy in the neoadjuvant therapy stage and the postoperative adverse reactions were evaluated	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks
Secondary	Quality of life measurement and evaluation 1	according to the QLQ-C30 scale of the Quality of Life Survey, the quality of life after neoadjuvant therapy was assessed	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks
Secondary	Quality of life measurement and evaluation 2	according to the QLQ-OES18 special scale for esophageal cancer, the quality of life after neoadjuvant therapy was assessed	From date of randomization until the date of first documented progression or date of death from any cause whichever came first, up to 100 weeks